Physician profile
Thadeus Dapash
NPI 1871976902
$22,233.08
in general payments reported to CMS, 2019-2025
47 companies · $8,797 in 2025
The $8,797 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $1,741 · 2021: $2,987 · 2022: $1,671 · 2023: $2,162 · 2024: $4,082 · 2025: $8,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,956.56 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,261.65 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $3,462.40 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,494.52 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,229.59 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $854.13 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $792.13 | 2024-2025 | Zenpep |
| Genzyme Corporation | $686.31 | 2023-2025 | |
| Vivus LLC | $546.37 | 2021-2025 | Pancreaze |
| Qol Medical, LLC | $475.96 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $455.03 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $453.19 | 2019-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $397.25 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $375.99 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $338.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $325.14 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $294.02 | 2022-2023 | Axonics |
| Ipsen Biopharmaceuticals, INC | $279.15 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Scientific Affairs, LLC | $273.92 | 2021-2024 | Tremfya |
| Novo Nordisk INC | $231.56 | 2019-2025 | Wegovy |
| Medtronic, INC. | $220.28 | 2024-2025 | Interstim, Gi Genius |
| Amgen INC. | $214.75 | 2020-2025 | Uplizna |
| Ferring Pharmaceuticals INC. | $202.99 | 2020-2025 | Rebyota |
| Gilead Sciences, INC. | $202.74 | 2023-2025 | Epclusa |
| Ironwood Pharmaceuticals, INC | $198.15 | 2020-2024 | |
| Redhill Biopharma INC. | $196.82 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $186.65 | 2021-2023 | |
| Celgene Corporation | $173.72 | 2022-2024 | Zeposia |
| Celltrion USA INC. | $166.12 | 2024-2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $159.80 | 2020-2024 | Ocaliva |
| 3-D Matrix, INC. | $144.11 | 2024 | |
| Braintree Laboratories, INC. | $126.52 | 2020-2023 | Suflave, Sutab |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2021 | |
| Allergan, INC. | $118.50 | 2019 | |
| Merck Sharp & Dohme LLC | $115.79 | 2022-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.72 | 2019 | |
| Organon LLC | $56.43 | 2024 | |
| Evoke Pharma, INC. | $42.80 | 2025 | |
| Exact Sciences Corporation | $41.31 | 2023 | Cologuard Collection Kit |
| Sandoz INC. | $37.15 | 2023-2024 | Hyrimoz |
| Eisai INC. | $32.93 | 2019-2024 | |
| Alcresta Therapeutics, INC. | $27.95 | 2024 | Relizorb |
| Biocon Biologics INC | $27.36 | 2025 | Yesintek |
| Mirum Pharmaceuticals, INC. | $22.84 | 2025 | Livmarli |
| Ultragenyx Pharmaceutical INC. | $19.12 | 2024 | Dojolvi |
| Fresenius Kabi USA, LLC | $18.02 | 2024 | Idacio |
| Invivyd INC | $17.57 | 2025 | Pemgarda |
| Astrazeneca Pharmaceuticals LP | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thadeus Dapash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.